A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Dermapharm Holding SE's Debt-to-Equity or its related term are showing as below:
CHIX:DMPd'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 1.79 Max: 4.01
Current: 1.42
During the past 13 years, the highest Debt-to-Equity Ratio of Dermapharm Holding SE was 4.01. The lowest was 0.01. And the median was 1.79.
CHIX:DMPd's Debt-to-Equity is ranked worse than 91.99% of 811
companies
in the Drug Manufacturers industry
Industry Median: 0.27
vs CHIX:DMPd: 1.42
Dermapharm Holding SE (CHIX:DMPd) Debt-to-Equity Explanation
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Dermapharm Holding SE Debt-to-Equity Related Terms
Dermapharm Holding SE Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Dermapharm Holding SE's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:DMPD vs ZTS, UTHR, VTRS: Debt-to-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Dermapharm Holding SE's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dermapharm Holding SE Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Dermapharm Holding SE's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Dermapharm Holding SE's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dermapharm Holding SE (CHIX:DMPD) has a Debt-to-Equity of 0.00 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Dermapharm Holding SE and its competitors. Over the past decade, Dermapharm Holding SE's Debt-to-Equity has ranged from 0.01 to 4.01. According to the industry distribution chart, Dermapharm Holding SE ranks #746 out of 811 companies in the Drug Manufacturers industry, placing it in the top 92%.
Is Dermapharm Holding SE's Debt-to-Equity too high?
Dermapharm Holding SE's current Debt-to-Equity is 0.00. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 4.01. Based on the distribution chart, Dermapharm Holding SE ranks #746 out of 811 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Dermapharm Holding SE has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does Dermapharm Holding SE's Debt-to-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Dermapharm Holding SE ranks #746 out of 811 companies for Debt-to-Equity. This places Dermapharm Holding SE in the lower half of its industry. The industry median Debt-to-Equity is 0.27. Historically, Dermapharm Holding SE's own Debt-to-Equity has ranged from 0.01 to 4.01 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Dermapharm Holding SE and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dermapharm Holding SE's current Debt-to-Equity is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dermapharm Holding SE stock overvalued right now?
Dermapharm Holding SE (CHIX:DMPD) has a current Debt-to-Equity of 0.00. The stock's GF Value™ is €39.87, compared to a current price of €46.18 — trading 15.8% above its estimated fair value. The current Debt-to-Equity is 0.00. Dermapharm Holding SE's overall GF Score™ is 80/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Dermapharm Holding SE (CHIX:DMPD), the current Debt-to-Equity is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dermapharm Holding SE (CHIX:DMPD) Overvalued in 2026?
Based on GuruFocus' analysis, Dermapharm Holding SE stock appears to be overvalued.
The current stock price of €46.18 is trading 15.8% above its estimated GF Value™ of €39.87.
Key valuation signals for CHIX:DMPD:
Debt-to-Equity: 0.00
GF Value™: €39.87 vs. price of €46.18 (15.8% above fair value)
No single metric tells the full story. See the CHIX:DMPD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dermapharm Holding SE manufactures patent-free branded pharmaceuticals for selected therapy fields, over-the-counter drugs, and natural remedies. The portfolio of the company includes cosmetics, nutritional supplements, and diet and medical devices. Business operating segments include Branded pharmaceuticals, which drive key revenue, Other healthcare products, and Parallel import business. The Branded pharmaceuticals segment covers numerous product areas through a wide variety of items sold under reputable brand names.
80GF Score
Get the complete analysis for CHIX:DMPD
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:DMPD has been successfully added to your 
